Ghana – one of the first countries to vaccinate against malaria through the pilot malaria vaccine implementation programme (MVIP), supported by Gavi – has granted full national licensure to the R21/Matrix-M malaria vaccine, developed by the University of Oxford and manufactured and scaled up by the Serum Institute of India (SII).
This second vaccine comes alongside the RTS,S vaccine, which was prequalified by the World Health Organization (WHO) in 2022 following a recommendation for its wider use in 2021. According to the WHO’s 2022 world malaria report, the disease killed 619,000 people in 2021 – with 96% of those deaths in the WHO African region, making malaria one of Africa’s biggest killers. Alongside existing interventions, this vaccine will help save more lives.








